COMMUNIQUÉS West-GlobeNewswire

SAFE Group signe un accord de distribution au Venezuela et annonce le succès de la première chirurgie

24/04/2025 - 18:00

SAFE Group signe un accord de distribution au Venezuela et annonce le succès de la première chirurgie Fleurieux-sur-l’Arbresle - France - le 24 avril 2025 à 18h . Safe SA (la « Société ») est fière d'annoncer la [...]

Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million

24/04/2025 - 18:00

Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million Halle (Saale) / Munich, Germany, April 24, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (“ Vivoryon ” or the “ [...]

Nerve Renew Under Review & Ingredients Guide | Best Nerve Pain Supplement Explained

24/04/2025 - 13:52

Nerve Renew is a dietary supplement formulated to support nerve health, particularly for individuals experiencing symptoms of peripheral neuropathy such as tingling, numbness, burning sensations, or nerve pain Eagle, [...]

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

24/04/2025 - 13:55

TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 [...]

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status

24/04/2025 - 13:57

WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with [...]

ORYZON Raises €30 Million in Capital Increase

24/04/2025 - 14:00

Issued 12,765,958 new shares Priced at €2.35 per share, representing a 15.44% discount on the 5-day VWAP Strong investor demand, with the offering significantly oversubscribed €15 million anchored by a leading US [...]

Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025

24/04/2025 - 14:00

ADC assay now available through ABS; customer study proves IO60 is a spatial workhorse MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, today [...]

Autonomize AI Prior Authorization Copilot: Helping Patients Get Care Faster, Safer, and with Less Stress

24/04/2025 - 14:00

AUSTIN, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Autonomize AI, the leader in healthcare-native AI, today announced a major update to its Prior Authorization Copilot that is delivering rapid, patient-centered [...]

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

24/04/2025 - 14:00

April 28 th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be held on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 24, 2025 [...]

Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas

24/04/2025 - 14:00

>8,500 samples and 100 million cells of high resolution and fully annotated spatial proteomics data available MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial [...]

X4 Pharmaceuticals Announces Reverse Stock Split

24/04/2025 - 14:00

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its board of directors has [...]

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

24/04/2025 - 14:00

CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]

Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025

24/04/2025 - 14:00

TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. [...]

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

24/04/2025 - 14:00

IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing [...]

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

24/04/2025 - 14:00

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, [...]

Carterra Announces its 2025 Symposia Series on Speeding Drug Discovery with AI/ML and Other New Technologies

24/04/2025 - 14:00

Presentations will be delivered by experts from a wide variety of leading research groups including Pfizer, GSK, and Bio-Techne, along with co-hosts IPA, ACROBiosystems, and Curia. SALT LAKE CITY, April 24, 2025 (GLOBE [...]

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

24/04/2025 - 14:00

CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]

Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

24/04/2025 - 14:00

Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025 Cocrystal Pharma’s pan-viral protease inhibitor [...]

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

24/04/2025 - 14:00

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the [...]